Samrat Pharmachem share price
BSE: 530125Pharmaceuticals & BiotechnologySmall Cap
Samrat Pharmachem Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995
Last close ₹271.35up ₹5.35 (2.01%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹266.00.
29 Oct: open ₹266.00, high ₹273.50, low ₹260.15
52-week range of traded prices to 29 Oct 2026
₹190.00Low, 30 Mar 2026₹309.85High, 30 Oct 2025
- Under BSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 14 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹84 Cr3,210th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.16
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 424
Results
Standalone; ₹ crore.Samrat Pharmachem quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −145.8%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹80 Crup 11.13%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹0.88 CrQuarter to Mar 2026: −₹2.04 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 1.1%
Revenue by quarter
Peak revenue ₹80 Cr, quarter to Jun 2026; lowest ₹63 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹0.88 CrA loss in 5 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 70.2 | 63.7 | 71.2 | 75.7 | 78.9 | 63.4 | 71.8 | 79.8 |
| Net profit | 2.7 | 2.8 | −0.4 | −0.2 | −0.6 | −0.5 | −2.0 | 0.9 |
| Net margin | 3.8% | 4.4% | −0.6% | −0.3% | −0.7% | −0.7% | −2.8% | 1.1% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹290 Crup 1.35%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹3.31 CrYear to Mar 2025: ₹7.11 Cr
- Net margin
- −1.1%
Revenue by year
Peak revenue ₹311 Cr, year to Mar 2023; lowest ₹71 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹3.31 CrA loss in 1 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71 | 93 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | 290 |
| Net profit | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 | 7 | −3 |
| Net margin | 2.2% | 3.5% | 1.4% | 3.1% | 3.0% | 7.7% | 5.4% | 0.8% | 2.5% | −1.1% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical Chemicals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months.Samrat Pharmachem PE ratio and valuation
Price to book
At or below today's level on 26% of 1,956 trading days since Nov 2018.
LowestHighest
Its median1.65Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 60% of 2,461 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −37.7% | – | – | 0.0% |
| 3 years | −19.1% | – | – | 0.2% |
| 5 years | +7.7% | – | – | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Samrat Pharmachem competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Samrat Pharmachem in market cap.Healthcare companies
Samrat Pharmachem is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Vaishali PharmaVAISHALI | 92 | 20.78 | 1.33 | – | – | 6.6% | 4.2% | 0.00% |
 Mercury LaboratoriesMERCURYLAB | 88 | 21.15 | 1.52 | −3.7% | +10.4% | 7.5% | 7.0% | 0.48% |
 Concord DrugsCONCORD | 87 | 42.38 | – | +82.5% | +380.5% | 5.0% | 7.1% | 0.00% |
 Denis Chem LabDENISCHEM | 86 | 10.72 | 0.93 | +4.1% | −5.8% | 9.0% | 10.4% | 4.06% |
 Amwill Health CareAMWILL | 83 | 7.44 | 1.00 | +21.4% | +38.7% | 14.4% | – | 1.20% |
 Cian HealthcareCHCL | 82 | – | 9.62 | −8.1% | – | −113.9% | – | 0.00% |
 Vilin Bio MedVILINBIO | 77 | 39.89 | 2.71 | +185.4% | +763.0% | 7.5% | – | 0.00% |
 Source Natural Foods & Herbal SupplSOURCENTRL | 73 | 19.35 | 2.82 | +63.1% | +20.6% | 15.6% | 16.7% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Samrat Pharmachem dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, in 4 years, the latest the year to Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 18 Sep 2025 | Final | ₹1.00 |
| 19 Sep 2024 | Final | ₹1.00 |
| 18 Sep 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 22 Sep 2022 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Samrat Pharmachem announcements
Sep 2026
28 Sep · Board meeting
Meeting on 14 Nov 2026: quarterly results24 Sep · Meeting
Aug 2026
Samrat Pharmachem share price by year
Each calendar year to 2025.Samrat Pharmachem share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 227.30 | −40.6% | 410.15 | 227.30 |
| 2024 | 382.65 | +9.9% | 637.15 | 323.45 |
| 2023 | 348.20 | −54.2% | 775.70 | 341.80 |
| 2022 | 759.50 | +116.1% | 1,202.15 | 356.00 |
| 2021 | 351.45 | +162.1% | 351.45 | 118.85 |
| 2020 | 134.10 | +37.0% | 151.65 | 56.05 |
| 2019 | 97.90 | +81.3% | 123.00 | 52.90 |
| 2018 | 54.00 | −44.0% | 164.30 | 49.25 |
| 2017 | 96.40 | +134.3% | 96.40 | 39.85 |
| 2016 | 41.15 | +14.8% | 45.15 | 25.45 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 269.00 | 273.00 | 255.20 | 266.00 | 261.77 | 1,301 |
| 27 Oct 2026 | 273.50 | 273.50 | 269.00 | 269.00 | 269.40 | 1,507 |
| 26 Oct 2026 | 295.00 | 298.00 | 269.00 | 274.85 | 277.87 | 1,763 |
| 23 Oct 2026 | 289.00 | 289.00 | 260.10 | 277.50 | 274.21 | 1,601 |
| 22 Oct 2026 | 278.00 | 294.00 | 277.95 | 288.10 | 287.25 | 7,733 |
| 21 Oct 2026 | 271.90 | 283.00 | 265.70 | 272.15 | 275.84 | 4,073 |
| 19 Oct 2026 | 254.20 | 279.60 | 254.20 | 270.15 | 272.77 | 9,287 |
| 16 Oct 2026 | 238.80 | 254.20 | 237.00 | 254.20 | 246.73 | 9,266 |
| 15 Oct 2026 | 241.90 | 241.90 | 230.00 | 231.10 | 234.73 | 1,165 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 530125
- ISIN
- INE103E01016
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.samratpharmachem.com
- CIN
- L24230GJ1992PLC017820
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1992
- Registered office
- Plot No A2/3445, GIDC Phase 4, Ankleshwar 393002, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments